Investigation of Desmoplastic Squamous Cell Carcinoma

Not Applicable

• Conditions: Squamous Cell Carcinoma of the Skin
• Interventions: Procedure: Immunohistochemistry using Pancytokeratin Staining

• Registration Number: NCT02717936
• Lead Sponsor: University Hospital Tuebingen

Brief Summary

Aim of the study is to verify wether it is possible to have a more sensitive diagnostic tool using pancytokeratin immunohistochemistry for desmoplastic squamous cell carcinoma compared to regular H\&E staining. The investigators therefore plan to include 73 participants with a confirmed diagnosis of desmoplastic squamous cell carcinoma and do regular follow up.

Detailed Description

Not available

Study Timeline

• Status Verified: 2016-01
• Study Start: 2016-01
• Study First Submitted: 2016-01-27
• Study First Submitted QC: 2016-03-18
• Study First Posted: 2016-03-24
• Last Update Submitted: 2016-03-24
• Last Update Posted: 2016-03-25
• Primary Completion: 2018-01
• Study Completion: 2020-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 73

Inclusion Criteria

• desmoplastic squamous cell carcinoma (SCC) of the skin

Exclusion Criteria

• tumor recurrence
• collision tumors
• other skin malignancies
• progeria
• Rothmund-Thomson-Syndrome
• lacking of the capacity for informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Immunohistochemistry	Immunohistochemistry using Pancytokeratin Staining	Patients are investigated using immunohistochemistry with Pancytokeratin

Primary Outcome Measures

Name	Time	Method
Recurrence free survival of patients with desmoplastic squamous cell carcinoma (SCC) diagnosed with immunohistochemistry .	4 years

Secondary Outcome Measures

Name	Time	Method
Presence of perineurial and perivascular tumor invasion according to histological work-up	4 years
Dimension of the tumor spreading according to histological work-up (measured in mm)	4 years
Histological pattern of tumour growth (continuous versus discontinuous)	4 years
Reduction of local recurrence with immunohistochemistry	4 years

Trial Locations

Locations (1)

Universityhospital; 🇩🇪 Tübingen, Baden-Württemberg, Germany